OBJECTIVES: The purpose of this study was to demonstrate the feasibility of percutaneous transvenous mitral valve-in-ring (VIR) implantation using the Melody valve in an ovine model. BACKGROUND: The recurrence of mitral regurgitation following surgical mitral valve (MV) repair in both adult and pediatric patients remains a significant clinical problem. Mitral annuloplasty rings are commonly used in MV repair procedures and may serve as secure landing zones for percutaneous valves. METHODS: Five sheep underwent surgical MV annuloplasty (24 mm, n = 2; 26 mm, n = 2; 28 mm, n = 1). Animals underwent cardiac catheterization with VIR implantation via a transfemoral venous, transatrial septal approach 1 week following surgery. Hemodynamic, angiographic, and echocardiographic data were recorded before and after VIR. RESULTS: VIR was technically successful and required <1 h of procedure time in all animals. Fluoroscopy demonstrated securely positioned Melody valves within the annuloplasty ring in all animals. Angiography revealed no significant MV regurgitation in 4 and moderate central MV regurgitation in the animal with the 28-mm annuloplasty. All animals demonstrated vigorous left ventricular function, no outflow tract obstruction, and no aortic valve insufficiency. CONCLUSIONS: This study demonstrated the feasibility of a purely percutaneous approach to MV replacement in patients with preexisting annuloplasty rings. This novel approach may be of particular benefit to patients with failed repair of ischemic mitral regurgitation and in pediatric patients with complex structural heart disease.
OBJECTIVES: The purpose of this study was to demonstrate the feasibility of percutaneous transvenous mitral valve-in-ring (VIR) implantation using the Melody valve in an ovine model. BACKGROUND: The recurrence of mitral regurgitation following surgical mitral valve (MV) repair in both adult and pediatric patients remains a significant clinical problem. Mitral annuloplasty rings are commonly used in MV repair procedures and may serve as secure landing zones for percutaneous valves. METHODS: Five sheep underwent surgical MV annuloplasty (24 mm, n = 2; 26 mm, n = 2; 28 mm, n = 1). Animals underwent cardiac catheterization with VIR implantation via a transfemoral venous, transatrial septal approach 1 week following surgery. Hemodynamic, angiographic, and echocardiographic data were recorded before and after VIR. RESULTS: VIR was technically successful and required <1 h of procedure time in all animals. Fluoroscopy demonstrated securely positioned Melody valves within the annuloplasty ring in all animals. Angiography revealed no significant MV regurgitation in 4 and moderate central MV regurgitation in the animal with the 28-mm annuloplasty. All animals demonstrated vigorous left ventricular function, no outflow tract obstruction, and no aortic valve insufficiency. CONCLUSIONS: This study demonstrated the feasibility of a purely percutaneous approach to MV replacement in patients with preexisting annuloplasty rings. This novel approach may be of particular benefit to patients with failed repair of ischemic mitral regurgitation and in pediatric patients with complex structural heart disease.
Authors: Liang Ma; Piergiorgio Tozzi; Christoph H Huber; Steven Taub; Gabrielle Gerelle; Ludwig K von Segesser Journal: Eur J Cardiothorac Surg Date: 2005-08 Impact factor: 4.191
Authors: Joerg Kempfert; Johannes Blumenstein; Michael W A Chu; Patrick Pritzwald-Stegmann; Tobias Kobilke; Volkmar Falk; Friedrich W Mohr; Thomas Walther Journal: Eur J Cardiothorac Surg Date: 2009-03-26 Impact factor: 4.191
Authors: Robert O Bonow; Blase A Carabello; Chatterjee Kanu; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-08-01 Impact factor: 29.690
Authors: P Bonhoeffer; Y Boudjemline; Z Saliba; J Merckx; Y Aggoun; D Bonnet; P Acar; J Le Bidois; D Sidi; J Kachaner Journal: Lancet Date: 2000-10-21 Impact factor: 79.321
Authors: Andrew M Atz; John A Hawkins; Minmin Lu; Meryl S Cohen; Steven D Colan; James Jaggers; Ronald V Lacro; Brian W McCrindle; Renee Margossian; Ralph S Mosca; Lynn A Sleeper; L LuAnn Minich Journal: J Thorac Cardiovasc Surg Date: 2010-12-15 Impact factor: 5.209
Authors: Edwin C McGee; A Marc Gillinov; Eugene H Blackstone; Jeevanantham Rajeswaran; Gideon Cohen; Farzad Najam; Takahiro Shiota; Joseph F Sabik; Bruce W Lytle; Patrick M McCarthy; Delos M Cosgrove Journal: J Thorac Cardiovasc Surg Date: 2004-12 Impact factor: 5.209
Authors: Thomas Walther; Jörg Kempfert; Michael A Borger; Jens Fassl; Volkmar Falk; Johannes Blumenstein; Mark Dehdashtian; Gerhard Schuler; Friedrich W Mohr Journal: Ann Thorac Surg Date: 2008-03 Impact factor: 4.330
Authors: Matthew J Gillespie; Chikashi Aoki; Satoshi Takebayashi; Toru Shimaoka; Jeremy R McGarvey; Robert C Gorman; Joseph H Gorman Journal: Ann Thorac Surg Date: 2015-04 Impact factor: 4.330
Authors: Adam B Greenbaum; Jose F Condado; Marvin Eng; Stamatios Lerakis; Dee Dee Wang; Dennis W Kim; Robert J Lederman; Gaetano Paone; William W O Neill; Vinod H Thourani; Vasilis C Babaliaros Journal: Catheter Cardiovasc Interv Date: 2017-05-04 Impact factor: 2.692